DDInter947 DDInter1658
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon gamma-1b
Interferon beta-1a {u} may lead to a major life threatening interaction when taken with {v} Tramadol
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Interferon gamma-1b
Interferon beta-1a may lead to a major life threatening interaction when taken with Tramadol